Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
10.59
+0.01 (0.09%)
At close: Dec 5, 2025, 4:00 PM EST
10.75
+0.16 (1.51%)
After-hours: Dec 5, 2025, 6:49 PM EST
Cullinan Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | - | - | - | - | 18.94 | - | |
| Gross Profit | - | - | - | - | 18.94 | - | |
| Selling, General & Admin | 56.49 | 54.02 | 42.49 | 40.19 | 29.15 | 17.12 | |
| Research & Development | 184.95 | 142.9 | 148.16 | 91.95 | 57.75 | 43.21 | |
| Operating Expenses | 241.44 | 196.92 | 190.65 | 132.14 | 86.9 | 60.34 | |
| Operating Income | -241.44 | -196.92 | -190.65 | -132.14 | -67.95 | -60.34 | |
| Interest & Investment Income | 25.11 | 29.66 | 21.63 | 6.61 | 0.48 | 0.89 | |
| Other Non Operating Income (Expenses) | -0.37 | -0.2 | 0.24 | 0.06 | -0.01 | -0.01 | |
| EBT Excluding Unusual Items | -216.7 | -167.46 | -168.78 | -125.47 | -67.49 | -59.46 | |
| Gain (Loss) on Sale of Assets | - | - | - | 276.79 | - | - | |
| Asset Writedown | - | - | -0.44 | - | - | - | |
| Pretax Income | -216.7 | -167.46 | -169.22 | 151.32 | -67.49 | -59.46 | |
| Income Tax Expense | 0.12 | 0.12 | -14.12 | 42.12 | - | - | |
| Earnings From Continuing Operations | -216.81 | -167.58 | -155.1 | 109.2 | -67.49 | -59.46 | |
| Minority Interest in Earnings | - | 0.19 | 1.94 | 2.02 | 1.92 | 7.66 | |
| Net Income | -216.81 | -167.38 | -153.16 | 111.21 | -65.57 | -51.8 | |
| Net Income to Common | -216.81 | -167.38 | -153.16 | 111.21 | -65.57 | -51.8 | |
| Shares Outstanding (Basic) | 59 | 54 | 42 | 45 | 43 | 20 | |
| Shares Outstanding (Diluted) | 59 | 54 | 42 | 47 | 43 | 20 | |
| Shares Change (YoY) | 18.23% | 29.41% | -10.91% | 8.27% | 116.61% | 2088.17% | |
| EPS (Basic) | -3.68 | -3.11 | -3.69 | 2.46 | -1.52 | -2.60 | |
| EPS (Diluted) | -3.68 | -3.11 | -3.69 | 2.38 | -1.52 | -2.60 | |
| Free Cash Flow | -174.31 | -145.3 | -134.48 | -127.8 | -43.43 | -29.78 | |
| Free Cash Flow Per Share | -2.96 | -2.70 | -3.24 | -2.74 | -1.01 | -1.50 | |
| Gross Margin | - | - | - | - | 100.00% | - | |
| Operating Margin | - | - | - | - | -358.73% | - | |
| Profit Margin | - | - | - | - | -346.14% | - | |
| Free Cash Flow Margin | - | - | - | - | -229.28% | - | |
| EBITDA | -241.13 | -196.61 | -190.34 | -132.04 | -67.9 | -60.27 | |
| D&A For EBITDA | 0.31 | 0.31 | 0.31 | 0.09 | 0.05 | 0.06 | |
| EBIT | -241.44 | -196.92 | -190.65 | -132.14 | -67.95 | -60.34 | |
| Effective Tax Rate | - | - | - | 27.84% | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.